Search hospitals > Pennsylvania > Bethlehem
Saint Luke's University Hospital-Bethlehem Campus
Claim this profileBethlehem, Pennsylvania 18015
Global Leader in Skin Cancer
Global Leader in Stomach Cancer
Conducts research for Breast Cancer
Conducts research for Relapse
Conducts research for Melanoma
209 reported clinical trials
19 medical researchers
Summary
Saint Luke's University Hospital-Bethlehem Campus is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Skin Cancer, Stomach Cancer, Breast Cancer, Relapse, Melanoma and other specialties. Saint Luke's University Hospital-Bethlehem Campus is involved with conducting 209 clinical trials across 350 conditions. There are 19 research doctors associated with this hospital, such as Melissa A. Wilson, Neil D. Belman, Darius Desai, and Gary Lu.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Stomach Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Melissa A. WilsonSt. Lukes University Health Network9 years of reported clinical research
Studies Skin Cancer
Studies Melanoma
5 reported clinical trials
9 drugs studied
Neil D. BelmanSaint Luke's University Hospital-Bethlehem Campus10 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
8 drugs studied
Darius DesaiSt. Luke's University Health Network - Allentown Cancer Center4 years of reported clinical research
Studies Pancreatic Cancer
Studies Skin Cancer
4 reported clinical trials
11 drugs studied
Gary LuSt. Lukes University Health Network5 years of reported clinical research
Studies Skin Cancer
Studies Melanoma
4 reported clinical trials
11 drugs studied
Clinical Trials running at Saint Luke's University Hospital-Bethlehem Campus
Skin Cancer
Breast Cancer
Lung Cancer
Ovarian Cancer
Breast cancer
Uterine Cancer
Non-Small Cell Lung Cancer
Stomach Cancer
Cancer
Uterine Tumors
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's University Hospital-Bethlehem Campus?
Saint Luke's University Hospital-Bethlehem Campus is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Skin Cancer, Stomach Cancer, Breast Cancer, Relapse, Melanoma and other specialties. Saint Luke's University Hospital-Bethlehem Campus is involved with conducting 209 clinical trials across 350 conditions. There are 19 research doctors associated with this hospital, such as Melissa A. Wilson, Neil D. Belman, Darius Desai, and Gary Lu.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.